Cargando…
Oncotype DX: Where Does It Stand in India?
Autores principales: | Batra, Atul, Patel, Amol, Gupta, Vineet Govinda, Mehta, Prashant, TVSVGK, Tilak, Biswas, Bivas, Pramanik, Raja, Das, Chandan Krishnan, Srivastava, Priyanka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690658/ https://www.ncbi.nlm.nih.gov/pubmed/31310569 http://dx.doi.org/10.1200/JGO.19.00151 |
Ejemplares similares
-
Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
por: Patel, Amol, et al.
Publicado: (2020) -
Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017) -
Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021) -
Reply to D. O'Reilly et al
por: Patel, Amol, et al.
Publicado: (2021) -
Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)